Evidence map›Paper›PMID 25274545›Full record

ArticleRetrovirology2014

Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.

Christopher J De Feo, Wei Wang, Meng-Lun Hsieh, Min Zhuang, Russell Vassell, Carol D Weiss

Abstract read
In one paragraph

Article in Retrovirology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Christopher J De FeoCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA. christopher.defeo@fda.hhs.gov.
Wei WangCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA. wei.wang@fda.hhs.gov.
Meng-Lun HsiehCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA. menglunhsieh@gmail.com.
Min ZhuangCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA. mznorthbethesda@gmail.com.
Russell VassellCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA. russell.vassell@fda.hhs.gov.
Carol D WeissCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA. carol.weiss@fda.hhs.gov.

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

backgroundThe HIV-1 envelope glycoprotein (Env) undergoes conformational changes that mediate fusion between virus and host cell membranes. These changes involve transient exposure of two heptad-repeat domains (HR1 and HR2) in the gp41 subunit and their subsequent self-assembly into a six-helix bundle (6HB) that drives fusion. Env residues and features that influence conformational changes and the rate of virus entry, however, are poorly understood. Peptides corresponding to HR1 and HR2 (N and C peptides, respectively) interrupt formation of the 6HB by binding to the heptad repeats of a fusion-intermediate conformation of Env, making the peptides valuable probes for studying Env conformational changes.

resultsUsing a panel of Envs that are resistant to N-peptide fusion inhibitors, we investigated relationships between virus entry kinetics, 6HB stability, and resistance to peptide fusion inhibitors to elucidate how HR1 and HR2 mutations affect Env conformational changes and virus entry. We found that gp41 resistance mutations increased 6HB stability without increasing entry kinetics. Similarly, we show that increased 6HB thermodynamic stability does not correlate with increased entry kinetics. Thus, N-peptide fusion inhibitors do not necessarily select for Envs with faster entry kinetics, nor does faster entry kinetics predict decreased potency of peptide fusion inhibitors.

conclusionsThese findings provide new insights into the relationship between 6HB stability and viral entry kinetics and mechanisms of resistance to inhibitors targeting fusion-intermediate conformations of Env. These studies further highlight how residues in HR1 and HR2 can influence virus entry by altering stability of the 6HB and possibly other conformations of Env that affect rate-limiting steps in HIV entry.

Indexed as

Drug Resistance, ViralProtein MultimerizationCell LineHIV-1HIV Envelope Protein gp41HIV Fusion InhibitorsHumansKineticsMultiprotein ComplexesMutant ProteinsProtein ConformationProtein StabilityThermodynamicsVirus Internalizationgp41 protein, Human immunodeficiency virus 1HIV Envelope Protein gp41HIV Fusion InhibitorsMultiprotein ComplexesMutant Proteins

Identifiers

PMID25274545
PMCPMC4190581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.